1006717-31-2
1006717-31-2
Chemical Structure
Alfuzosin-d6
Synonym(s): SL 77499-d6
- CAS. Nr.: 1006717-31-2
- Formula:C19H21D6N5O4
- Molecular Weight:395.49
InChIKey: WNMJYKCGWZFFKR-XERRXZQWSA-N
SMILES: NC1=NC(N(C)CCCNC(C2CCCO2)=O)=NC3=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C3
Biological Activity: Alfuzosin-d6 (SL 77499-d6) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Alfuzosin-d6 | Alfuzosin-d6 (SL 77499-d6) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alfuzosin (Standard) | ≥98% | Alfuzosin (Standard) is the analytical standard of Alfuzosin. This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alfuzosin-d7 | Alfuzosin-d7 is the deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alfuzosin-13C,d3 | Alfuzosin-13C,d3 is the 13C- and deuterium labeled Alfuzosin. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alfuzosin-d3 | 99.90% | Alfuzosin-d3 is deuterium labeled Alfuzosin. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alfuzosin | 99.86% | Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Martin DJ, et al. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci. 1998;63(3):169-76. [Content Brief]
- [3]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. [Content Brief]
